MB
MBX

MPM BioImpact’s MBX Biosciences MBX Stock Holding History

MPM BioImpact’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,294,416
Closed -$14.8M – 51
2025
Q2 		$14.8M Buy
1,294,416
+161,466
+14% +$1.64M 2.56% 14
2025
Q1 		$8.36M Buy
+1,132,950
New +$12M 1.44% 31

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact's MBX Position: Q3 2025 in Review

MPM BioImpact sold out of MBX Biosciences (MBX) in Q3 2025, closing a stake of 1,294,416 shares — an estimated $14.8M sold.

MPM BioImpact first reported a position in MBX in Q1 2025 and held it in 2 quarters. The position peaked at $14.8M in Q2 2025. 118 funds tracked by Wall St. Rank hold MBX as of Q3 2025.

  • MPM BioImpact reported no remaining MBX Biosciences position as of Q3 2025 after selling out during the quarter.
  • MPM BioImpact sold 1,294,416 MBX Biosciences shares in Q3 2025, an estimated $14.8M.
  • MPM BioImpact first reported a position in MBX Biosciences in Q1 2025 and held it in 2 quarters.
  • MPM BioImpact's MBX Biosciences position peaked at $14.8M in Q2 2025.
  • 118 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2025.

Based on MPM BioImpact's 13F filing for Q3 2025, filed 14 Nov 2025.